Gyre Therapeutics (GYRE) Invested Capital (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Invested Capital data on file, last reported at $137.0 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $137.0 million, up 31.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $137.0 million (up 31.33% YoY), and the FY2025 annual result was $106.0 million, up 7.75% from the prior year.
• Invested Capital rose to $137.0 million in Q1 2026 per GYRE's latest filing, from $106.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $137.0 million in Q1 2026 and troughed at $13.9 million in Q4 2023.
• A 5-year average of $83.5 million and a median of $88.8 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2024: Invested Capital plunged 80.68% in 2023, then surged 605.44% in 2024.
• A 5-year view of Invested Capital shows it stood at $72.2 million in 2022, then sank by 80.68% to $13.9 million in 2023, then surged by 605.44% to $98.4 million in 2024, then increased by 7.75% to $106.0 million in 2025, then climbed by 29.19% to $137.0 million in 2026.
• Business Quant data shows GYRE's Invested Capital at $137.0 million in Q1 2026, $106.0 million in Q4 2025, and $101.9 million in Q3 2025.